R-Biopharm   Report issue

For profit Phase 1 Phase 3
Founded: Darmstadt Germany (1988)
Status: No NME R&D (1988)

Organization Overview

First Clinical Trial
2017
NCT03979898
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

R-Bio

Active Ingredients

Drugs in Phase 3 Trials (1)

allogeneic adipose derived mesenchymal stem cell (4 trials)

Drugs in Phase 1 Trials (1)

astrostem (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Cerebral Palsy (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2